236 related articles for article (PubMed ID: 37568798)
21. Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
Aggen DH; Chu CE; Rosenberg JE
Clin Cancer Res; 2023 Apr; 29(8):1377-1380. PubMed ID: 36749325
[TBL] [Abstract][Full Text] [Related]
22. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
23. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
Penny CL; Quow K; Rundle CW; Al-Rohil RN; Cardones AR; Kheterpal MK; Fresco AI
Br J Dermatol; 2022 Jul; 187(1):126-127. PubMed ID: 35048357
[TBL] [Abstract][Full Text] [Related]
24. The prognostic significance of Nectin-2 and Nectin-4 expression in glial tumors.
Dekanić A; Babarović E; Kučan Brlić P; Knežić M; Savić Vuković A; Mazor M; Jonjić N
Pathol Res Pract; 2023 Apr; 244():154416. PubMed ID: 36989846
[TBL] [Abstract][Full Text] [Related]
25. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
26. An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.
Ren Y; Liu T; Li S; Ma X; Xia L; Wang P; Guo Q; Yao Y; Hou X; Sheng X; Zhu H; Yang Z
Int J Pharm; 2024 Feb; 651():123756. PubMed ID: 38160990
[TBL] [Abstract][Full Text] [Related]
27. Tracing the evolution of nectin and nectin-like cell adhesion molecules.
Duraivelan K; Samanta D
Sci Rep; 2020 Jun; 10(1):9434. PubMed ID: 32523039
[TBL] [Abstract][Full Text] [Related]
28. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
[TBL] [Abstract][Full Text] [Related]
30. Nectin spot: a novel type of nectin-mediated cell adhesion apparatus.
Mizutani K; Takai Y
Biochem J; 2016 Sep; 473(18):2691-715. PubMed ID: 27621480
[TBL] [Abstract][Full Text] [Related]
31. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
[TBL] [Abstract][Full Text] [Related]
32. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
Bouleftour W; Sargos P; Magne N
Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077
[TBL] [Abstract][Full Text] [Related]
33. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
Tomiyama E; Fujita K; Rodriguez Pena MDC; Taheri D; Banno E; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Yamaguchi S; Fushimi H; Yoshimura K; Uemura H; Netto GJ; Nonomura N
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751328
[TBL] [Abstract][Full Text] [Related]
34. Tage4/Nectin-like molecule-5 heterophilically trans-interacts with cell adhesion molecule Nectin-3 and enhances cell migration.
Ikeda W; Kakunaga S; Itoh S; Shingai T; Takekuni K; Satoh K; Inoue Y; Hamaguchi A; Morimoto K; Takeuchi M; Imai T; Takai Y
J Biol Chem; 2003 Jul; 278(30):28167-72. PubMed ID: 12740392
[TBL] [Abstract][Full Text] [Related]
35. Regarding "Management of Dermatologic Events Associated with the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin".
Ingen-Housz-Oro S; Thibault C; Sohier P; Dupin N
Oncologist; 2022 Oct; 27(10):e825-e826. PubMed ID: 36036595
[TBL] [Abstract][Full Text] [Related]
36. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
37. Membrane palmitoylated proteins regulate trafficking and processing of nectins.
Dudak A; Kim J; Cheong B; Federoff HJ; Lim ST
Eur J Cell Biol; 2011 May; 90(5):365-75. PubMed ID: 21371776
[TBL] [Abstract][Full Text] [Related]
38. Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis.
Izumi H; Hirabayashi K; Nakamura N; Nakagohri T
Surg Today; 2015 Apr; 45(4):487-94. PubMed ID: 25690753
[TBL] [Abstract][Full Text] [Related]
39. Emerging roles of the nectin family of cell adhesion molecules in tumour-associated pathways.
Duraivelan K; Samanta D
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188589. PubMed ID: 34237351
[TBL] [Abstract][Full Text] [Related]
40. Different roles of the three loops forming the adhesive interface of nectin-4 in measles virus binding and cell entry, nectin-4 homodimerization, and heterodimerization with nectin-1.
Mateo M; Navaratnarajah CK; Willenbring RC; Maroun JW; Iankov I; Lopez M; Sinn PL; Cattaneo R
J Virol; 2014 Dec; 88(24):14161-71. PubMed ID: 25275122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
